Why the study?
Does changing to clopidogrel 75 mg/d reduce the composite of death, myocardial infarction, ischemic stroke, and unstable angina in patients with stable coronary artery disease compared to continuing aspirin 160 mg/d?
Does changing to clopidogrel 75 mg/d reduce the composite of death, myocardial infarction, ischemic stroke, and unstable angina in patients with stable coronary artery disease compared to continuing aspirin 160 mg/d?
In stable CAD patients, high on-aspirin residual platelet reactivity did not predict worse clinical outcomes and did not identify a subgroup that benefited from switching to clopidogrel.
No takes yet. Share an insight, caveat, or question.
High on-aspirin RPR does not identify patients benefiting from clopidogrel switch in stable CAD; challenges platelet reactivity-guided therapy.
Pettersen et al. (2012) studied this question.